enGene Q3 net loss widens to $32.5 million as operating expenses rise
enGene Therapeutics reported a third-quarter net loss of $32.5 million, or $0.47 per share, for the three months ended July 31, 2026, up from $29.0 million, or $0.57 per share, a year earlier. Total operating expenses rose to $34.0 million from $29.9 million, and the company ended the quarter with $266.3 million in cash, cash equivalents, and marketable securities, which it said will support its planned BLA submission for detalimogene.
Key points
- Q3 net loss attributable to common shareholders: $32.5 million ($0.47 per share), versus $29.0 million ($0.57 per share) a year earlier
- Total operating expenses: $34.0 million, versus $29.9 million; general and administrative expenses rose $6.6 million, partly due to workforce reduction-related costs
- Cash, cash equivalents, and marketable securities: $266.3 million as of July 31, 2026
- Pre-BLA meeting with the FDA and initiation of the detalimogene BLA submission are both planned for 4Q 2026
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.